Research To Practice | Oncology Videos Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Breast Cancer
Jun 26, 2023
02:30:31
Featuring perspectives from Dr Komal Jhaveri, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O'Shaughnessy, Dr Hope S Rugo and Prof Peter Schmid, including the following topics:
- Long-Term Management of HER2-Positive Breast Cancer
- Introduction (0:00)
- Management of CNS-only disease progression in patients with HER2-positive metastatic breast cancer (2:27)
- Synergy between tucatinib and HER2-targeted antibody-drug conjugates (5:24)
- Management of trastuzumab deruxtecan–related adverse events (7:41)
- Patient selection for and practical implementation of postadjuvant neratinib (13:23)
- Faculty presentation: Dr Krop (16:26)
- Optimizing the Management of ER-Positive Localized Breast Cancer
- Ovarian function suppression to preserve fertility and prevent premature ovarian insufficiency; interrupting adjuvant hormonal therapy to attempt pregnancy (24:56)
- Selection of patients for adjuvant tamoxifen monotherapy (29:05)
- Utility of genomic assays in the neoadjuvant setting; management of node-positive disease in postmenopausal patients with low-risk Recurrence Scores® (33:35)
- Selection between abemaciclib and ribociclib in the adjuvant setting (36:45)
- Potential utility of circulating tumor DNA assessment in breast cancer (41:58)
- Faculty presentation: Dr Kalinsky (46:36)
- Considerations in the Care of Patients with ER-Positive Metastatic Breast Cancer
- Preference of CDK4/6 inhibitor in the metastatic setting (56:42)
- Sequencing of trastuzumab deruxtecan in ER-positive, HER2-low metastatic breast cancer (59:00)
- Faculty presentation: Dr Jhaveri (1:06:39)
- Novel and Emerging Strategies for ER-Positive Metastatic Breast Cancer
- Selection of therapy for ER-positive metastatic breast cancer progressing on a CDK4/6 inhibitor; future role of capivasertib (1:19:31)
- Faculty presentation: Dr Rugo (1:30:39)
- Evolving Clinical Decision-Making for Localized Triple-Negative Breast Cancer (TNBC)
- Management of localized TNBC; selection of patients for adjuvant Olaparib (1:46:10)
- PARP inhibitor tolerability (1:51:55)
- Faculty presentation: Dr O'Shaughnessy (1:55:31)
- Recent Advances in the Treatment of Metastatic TNBC (mTNBC)
- Selection of therapy for triple-negative metastatic breast cancer; sequencing of trastuzumab deruxtecan in ER-negative, HER2-low disease (2:11:08)
- Faculty presentation: Prof Schmid (2:18:03)